Osorio, Marta <br/><br/>
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study.  [electronic resource] 

 -  Cancer biology & therapy  Apr 2008 
 - 488-95 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.7.4.5476  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Bacterial Outer Membrane Proteins--immunology<br/>Cancer Vaccines--immunology<br/>Eye Neoplasms--drug therapy<br/>Female<br/>G(M3) Ganglioside--analogs & derivatives<br/>Humans<br/>Immunoglobulin A--blood<br/>Immunoglobulin G--blood<br/>Immunoglobulin M--blood<br/>Liposomes<br/>Male<br/>Mannitol--administration & dosage<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Neisseria meningitidis--immunology<br/>Oleic Acids--administration & dosage<br/>Skin Diseases--drug therapy<br/>Survival Analysis<br/>Treatment Outcome<br/>Vaccination<br/>Vitiligo--immunology